Lek's sponsorship of the Biennial of Graphic Arts helps support art in Slovenia
- In seven years of cooperation, Lek has donated over EUR 56,000 to the International Centre of Graphic Arts for its programs and events.
- The Biennial of Graphic Arts is not only a top-level art event, but also a shining example of cooperation between the business world and the art world.
- The 28th Biennial of Graphic Arts is a diverse event with a long-standing tradition, made up of numerous exhibitions and events.
The doors were opened today to the 28th Biennial of Graphic Art, an event that receives regular support from Lek, a Sandoz company.
The International Centre of Graphic Arts and Lek, a Sandoz company, have been working together for many years. We joined our efforts at the graphic arts biennials in 2003, 2005 and 2007, and at exhibitions by Alan Hranitelj in 2006 and Petra Varl and Zora Stančič in 2008. Each time it has been shown that business and the arts mix so well that they bring forth exceptional results, so this year we have decided to be a part of this significant cultural event once again.
“The Biennial of Graphic Arts is an excellent example of a cultural project which has for many years clearly indicated the importance and effect of creative cooperation between business and the arts. Like Lek, they too strive for excellence in the organization of every event and through their long-term success ensure the continued development of the arts in Slovenia,” said Lek CEO Vojmir Urlep.
The winner of the Grand Prize at the 28th Biennial of Graphic Arts is the group Justseeds from the United States of America. Justseeds Artists’ Cooperative is a decentralized community of artists who have banded together to promote their individual work, to collaborate with and encourage each other, and to support progressive social movements.
The central exhibition at the 28th Biennial of Graphic Arts was titled The Matrix: Unstable Reality. It attempts to respond to certain vital questions for society and art raised by the cult movie trilogy The Matrix. Does a medium stay the same once it incorporates new technologies in its discourse? Does this increase the audience for art? What is the social power of those who possess the matrix? Is the possession of the matrix enough to also justify exclusive reproduction rights? Can we create a perfect world, whether real or virtual?
The exhibition offers a selection of more than eighty internationally established and emerging artists. Their work extends from traditional and contemporary printmaking to artist’s books and interventions in the public space, in the mass media, and on computers. The exhibition’s art director is Božidar Zrinski.
In addition to the main exhibition space at the International Centre of Graphic Arts, exhibitions within the Biennial of Graphic Arts are also held at the Jakopič Gallery, Cankarjev dom Gallery, the Alkatraz, Ganes Pratt, Kapsula and Škuc galleries, on the Jakopič Promenade, at the Pionirski dom Art Center, at the Slovenian Ethnographic Museum and at the Kinodvor Coffee Shop.
The 28th Biennial of Graphic Arts is produced by the International Centre of Graphic Arts and co-producers Cankarjev dom Cultural and Congress Centre, Alkatraz Gallery, Ganes Pratt Gallery, Kapsula Gallery, Škuc Gallery, the City Museum and Galleries of Ljubljana, Pionirski dom Art Center, Stripburger/Forum Ljubljana, and the National Education Institute.
Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biosimilar products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz global markets. For further information please visit http://www.lek.si/eng/
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (US). In 2008, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.6 billion. For further information please visit www.sandoz.com
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96,700 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For further information contact:
Katarina Klemenc Dinjaški
Lek Pharmaceuticals d.d.
Phone: + 386 1 580 22 43
Fax: + 386 1 580 24 32